SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies ...
Verywell Health on MSN
New diabetic macular edema treatment cuts monthly eye injections to twice a year
Fact checked by Jennifer Klump Key Takeaways Susvimo is an FDA-approved eye implant for diabetic macular edema that can be refilled every six months instead of requiring monthly injections.Diabetic ...
Please provide your email address to receive an email when new articles are posted on . Genentech plans to reintroduce Susvimo for the treatment of wet age-related macular degeneration. The company is ...
– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per ...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results